Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Norway
  4. Oslo Bors
  5. BerGenBio ASA
  6. News
  7. Summary
    BGBIO   NO0010650013

BERGENBIO ASA

(BGBIO)
  Report
Real-time Oslo Bors  -  10:25 2022-10-04 am EDT
6.355 NOK   +1.68%
09/27BerGenBio Starts Mid-Stage Trial of COVID-19 Drug for Hospitalized Patients
MT
09/27BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Platform for Hospitalized Covid-19 Patients
CI
09/27Bergenbio annouces first patient randomized in bemcentinib trial in eu-solidact platform for hospitalized covid-19 patients
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BERGENBIO ASA
09/27BerGenBio Starts Mid-Stage Trial of COVID-19 Drug for Hospitalized Patients
MT
09/27BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Pl..
CI
09/27Bergenbio annouces first patient randomized in bemcentinib trial in eu-solidact platfor..
AQ
09/07BerGenBio to Present at Pareto Securities' 13th Annual Healthcare Conference
AQ
08/23BerGenBio ASA Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/23Transcript : BerGenBio ASA, Q2 2022 Earnings Call, Aug 23, 2022
CI
08/23BerGenBio reports second quarter and half year 2022 financial results and provides busi..
AQ
08/09Bergenbio Asa : Invitation to second quarter and half year 2022 results webcast
AQ
06/16BerGenBio - Mandatory notification of trade by Primary Insider
AQ
06/06Bergenbio presents clinical data on bemcentinib in combination with docetaxel in patien..
AQ
05/25Bergenbio asa - results for the first quarter 2022
AQ
05/24BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/24BerGenBio ASA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/24Transcript : BerGenBio ASA, Q1 2022 Earnings Call, May 24, 2022
CI
05/24Bergenbio Asa : Results for the first quarter 2022
AQ
More most relevant news
All news about BERGENBIO ASA
09/27BerGenBio Starts Mid-Stage Trial of COVID-19 Drug for Hospitalized Patients
MT
09/27BerGenBio ASA Announces First Patient Randomized in Bemcentinib Trial in Eu-Solidact Pl..
CI
09/27Bergenbio annouces first patient randomized in bemcentinib trial in eu-solidact platfor..
AQ
09/07BerGenBio to Present at Pareto Securities' 13th Annual Healthcare Conference
AQ
08/23BerGenBio ASA Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/23Transcript : BerGenBio ASA, Q2 2022 Earnings Call, Aug 23, 2022
CI
08/23BerGenBio reports second quarter and half year 2022 financial results and provides busi..
AQ
08/09Bergenbio Asa : Invitation to second quarter and half year 2022 results webcast
AQ
06/16BerGenBio - Mandatory notification of trade by Primary Insider
AQ
06/06Bergenbio presents clinical data on bemcentinib in combination with docetaxel in patien..
AQ
More news
News in other languages on BERGENBIO ASA
09/27BerGenBio démarre un essai de mi-parcours du médicament COVID-19 pour les patients hosp..
09/27BerGenBio ASA annonce le premier patient randomisé dans l'essai du bemcentinib sur la p..
08/23BerGenBio ASA annonce ses résultats pour le deuxième trimestre et le semestre clos le 3..
05/24BerGenBio ASA annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/24BerGenBio ASA annonce ses résultats pour le premier trimestre clos le 31 mars 2022
05/04BerGenBio va se concentrer sur COVID-19, le cancer du poumon non à petites cellules
04/26BerGenBio ASA annonce l'analyse complète des données de l'étude Accord2 de phase II sur..
04/25Bergenbio présente les données de l'essai clinique Bemcentinib Covid-19 à l'Eccmid 2022
04/11L'entreprise norvégienne BerGenBio nomme un directeur médical en chef
04/11BerGenBio ASA nomme Cristina Oliva au poste de médecin en chef, à compter du 25 avril 2..
More news
Press releases
09/27Bergenbio annouces first patient randomized in bemcentinib trial in eu-solidact platfor..
AQ
09/07BerGenBio to Present at Pareto Securities' 13th Annual Healthcare Conference
AQ
08/23BerGenBio reports second quarter and half year 2022 financial results and provides busi..
AQ
08/09Bergenbio Asa : Invitation to second quarter and half year 2022 results webcast
AQ
06/16BerGenBio - Mandatory notification of trade by Primary Insider
AQ
More press releases
Upcoming event on BERGENBIO ASA